Allergy Therapeutics PLC Stock
Your prediction
Allergy Therapeutics PLC Stock
Allergy Therapeutics PLC took a tumble today and lost -€0.006 (-14.470%).
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | -14.470% | 26.667% | 31.034% | -20.000% | 76.744% | -83.478% | - |
| Alliance Pharma plc | 1.140% | -7.368% | -14.563% | -52.109% | -12.871% | -67.706% | - |
| Cellectar BioSciences Inc. | -1.960% | 5.517% | -11.561% | 118.571% | 34.211% | -72.920% | - |
| Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | -3.670% | 2.439% | -4.545% | -55.789% | -26.957% |
News
Want an Extra $500 in Annual Dividend Income? Invest $5,890 in These 3 High-Yield Dividend Stocks.
Investors eager to bulk up their passive income streams can do so without breaking the bank.
At recent prices, Hercules Capital (NYSE: HTGC), Altria Group (NYSE: MO), and AT&T (NYSE: T) offer an
1 Wall Street Analyst Thinks AT&T Stock Is Going to $20. Is It a Buy?
AT&T (NYSE: T) stock has struggled in recent years, but Barclays analyst Kannan Venkateshwar believes the company deserves a higher valuation, considering the recent subscriber gains for its
Better Dividend Stock: AT&T vs. Verizon
Income-seeking investors want to turn their heads toward the telecommunications industry. Two members of America's three-way telecom oligopoly offer huge dividend yields above 6% at the moment.
Veri